AstraZeneca's lung cancer trial has finished enrollment; results are expected in 2027.

AstraZeneca's PACIFIC-9 Phase 3 trial, evaluating durvalumab with monalizumab or oleclumab for unresectable Stage III NSCLC, has completed enrollment. Results are now expected in the first half of 2027, delayed from the second half of 2026. Monalizumab is developed by Innate Pharma in collaboration with AstraZeneca.

Original reporting
Published Oct 27, 2026, 6:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 6:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$AZN
Neutral
medium confidence
Mentioned
$AZN · $IPHA
Relevance
7/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$AZNNeutralMed
01

Why it matters

The timing shift may temper short‑term enthusiasm for both companies, but does not alter the long‑term potential of the therapy.

02

Market read

Trial readout delay is a material update for investors in oncology biotech, affecting AZN and IPHA valuations.

03

What to watch

Potential for additional data collection may improve eventual efficacy readout, offsetting timing concerns.

Relevance 7/10Novelty 7/10Timing: future, readout now expected H1 2027

Background

AstraZeneca leads the PACIFIC-9 Phase 3 trial of durvalumab with Innate Pharma's antibodies. Enrollment is complete, but the high‑level data readout has been pushed to early 2027.

Company-level read

Ticker impact

$AZNNeutralMedium confidence
Context

AstraZeneca updated the PACIFIC-9 Phase 3 trial readout to H1 2027, delaying expected data.

Expected impact

likely modest downside as investors price in a later data readout

Evidence & confidence

Trial timeline shifts are material for biotech stocks but the impact is gradual and depends on future data.

$IPHANeutralMedium confidence
Context

Innate Pharma announced the trial timing change for its partner AstraZeneca, confirming enrollment is complete.

Expected impact

potential slight pressure as the market adjusts expectations for monalizumab data

Evidence & confidence

The company’s value is tied to the upcoming readout; a later date reduces near‑term upside.

Market effects

Oncology trial timelines may cause broader caution in biotech sector.

European biotech listings could see modest re‑rating.

Limited to investors tracking cancer immunotherapy pipelines.

Counterpoint

The delay could be seen as a positive sign that the trial is proceeding without safety setbacks.

Key entities

  • AstraZeneca

    Global pharmaceutical firm leading the trial.

  • Innate Pharma

    Biotech partner developing monalizumab and oleclumab.

Related articles

$IPHAHighAI 8/10

Why is Innate Pharma stock sliding today?

Innate Pharma (IPH) shares fell 21.1% to $1.05 after presenting Phase 1 clinical data for IPH4502. The drug showed a 33% response rate in non-urothelial tumors but modest results in urothelial cancer, its primary target. BTIG had a $9.00 price target, but the data underwhelmed, leading to a 52-week low of $1.01. The broader market decline also contributed to the sell-off.

$SMMTMedAI 8/10

FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK

FDA rejected Summit Therapeutics' ivonescimab for lung cancer, citing insufficient benefits. Sellas Life Sciences' cancer vaccine showed 41% reduced death risk in a Phase 3 trial. GSK's Nelkarmi, acquired via Nuvalent buyout, gained FDA approval for lung cancer. AstraZeneca's gefurulimab was approved for myasthenia gravis. Eli Lilly partnered with Stipple Bio for cancer drugs, potentially worth $5.9B. Biogen invested $32M in Trimtech for neurodegenerative disease treatments.